Search

Your search keyword '"Scheffold, Christian"' showing total 199 results
Start Over Author "Scheffold, Christian" Publication Year Range Last 50 years
199 results on '"Scheffold, Christian"'

1. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

Author

Pal, Sumanta Kumar, Albiges, Laurence, Tomczak, Piotr, Suárez, Cristina, Voss, Martin H, de Velasco, Guillermo, Chahoud, Jad, Mochalova, Anastasia, Procopio, Giuseppe, Mahammedi, Hakim, Zengerling, Friedemann, Kim, Chan, Osawa, Takahiro, Angel, Martín, Gupta, Suyasha, Khan, Omara, Bergthold, Guillaume, Liu, Bo, Kalaitzidou, Melania, Huseni, Mahrukh, Scheffold, Christian, Powles, Thomas, and Choueiri, Toni K

Published
2023
Full Text
View/download PDF

3. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

Author

Motzer, Robert J, Powles, Thomas, Burotto, Mauricio, Escudier, Bernard, Bourlon, Maria T, Shah, Amishi Y, Suárez, Cristina, Hamzaj, Alketa, Porta, Camillo, Hocking, Christopher M, Kessler, Elizabeth R, Gurney, Howard, Tomita, Yoshihiko, Bedke, Jens, Zhang, Joshua, Simsek, Burcin, Scheffold, Christian, Apolo, Andrea B, and Choueiri, Toni K

Published
2022
Full Text
View/download PDF

4. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

Author

Schöffski, Patrick, Gordon, Michael, Smith, David C, Kurzrock, Razelle, Daud, Adil, Vogelzang, Nicholas J, Lee, Yihua, Scheffold, Christian, and Shapiro, Geoffrey I

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Trials and Supportive Activities, Clinical Research, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Anilides, Antineoplastic Agents, Belgium, Disease Progression, Disease-Free Survival, Drug Administration Schedule, Early Termination of Clinical Trials, Female, Humans, Israel, Kaplan-Meier Estimate, Male, Neoplasms, Protein Kinase Inhibitors, Pyridines, Taiwan, Time Factors, Treatment Outcome, United States, Cabozantinib, Vascular endothelial growth factor receptor, Solid tumour, Objective response rate, Progression-free survival, Randomised discontinuation trial, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Cabozantinib is an inhibitor of tyrosine kinases, including MET, vascular endothelial growth factor receptor, AXL and RET. This multi-cohort phase II randomised discontinuation trial explored anticancer activity of cabozantinib in nine tumour types.Cabozantinib was administered (100 mg, once daily) to patients with advanced, recurrent or metastatic cancers. Those with stable disease at week 12 were randomised 1:1 to cabozantinib or placebo. Primary end-points were objective response rate (ORR) at week 12 and progression-free survival (PFS) in the randomised phase.A total of 526 patients were enrolled. The highest ORR was observed in ovarian cancer (OC) (21.7%); the largest PFS benefit was observed in castration-resistant prostate cancer (CRPC) (median 5.5 versus 1.4 months for placebo; hazard ratio 0.14, 95% confidence interval: 0.04, 0.52). Disease control rates were >40% for CRPC, OC, melanoma, metastatic breast cancer (MBC), hepatocellular carcinoma (HCC) and non-small cell lung cancer. Median duration of response ranged from 3.3 (MBC) to 11.2 months (OC). Encouraging efficacy results and symptomatic improvements prompted early suspension of the randomised stage and conversion to open-label non-randomised expansion cohorts. Dose reductions to manage adverse events (AEs) occurred in 48.7% of patients. The most frequent grade III-IV AEs were fatigue (12.4%), diarrhoea (10.5%), hypertension (10.5%) and palmar-plantar erythrodysesthesia syndrome (8.7%).Clinical antitumour activity of cabozantinib was observed in a subset of tumour types: CRPC and OC were evaluated further in expansion cohorts. Phase III programs were initiated in CRPC and HCC. Interpretation of efficacy outcomes was limited by early termination of the randomised portion of the trial.NCT00940225.

Published
2017

7. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

Author

Choueiri, Toni K., Hessel, Colin, Halabi, Susan, Sanford, Ben, Michaelson, M. Dror, Hahn, Olwen, Walsh, Meghara, Olencki, Thomas, Picus, Joel, Small, Eric J., Dakhil, Shaker, Feldman, Darren R., Mangeshkar, Milan, Scheffold, Christian, George, Daniel, and Morris, Michael J.

Published
2018
Full Text
View/download PDF

8. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

Author

Smith, David C, Smith, Matthew R, Sweeney, Christopher, Elfiky, Aymen A, Logothetis, Christopher, Corn, Paul G, Vogelzang, Nicholas J, Small, Eric J, Harzstark, Andrea L, Gordon, Michael S, Vaishampayan, Ulka N, Haas, Naomi B, Spira, Alexander I, Lara, Primo N, Lin, Chia-Chi, Srinivas, Sandy, Sella, Avishay, Schöffski, Patrick, Scheffold, Christian, Weitzman, Aaron L, and Hussain, Maha

Subjects
Urologic Diseases, Clinical Trials and Supportive Activities, Prostate Cancer, Cancer, Aging, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Musculoskeletal, Aged, Aged, 80 and over, Alkaline Phosphatase, Anilides, Antineoplastic Agents, Biomarkers, Tumor, Bone Neoplasms, Bone Remodeling, Collagen Type I, Disease-Free Survival, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Lymphatic Metastasis, Male, Middle Aged, Orchiectomy, Peptides, Prostatic Neoplasms, Pyridines, Receptor Protein-Tyrosine Kinases, Treatment Outcome, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeCabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. We evaluated the activity of cabozantinib in patients with castration-resistant prostate cancer (CRPC) in a phase II randomized discontinuation trial with an expansion cohort.Patients and methodsPatients received 100 mg of cabozantinib daily. Those with stable disease per RECIST at 12 weeks were randomly assigned to cabozantinib or placebo. Primary end points were objective response rate at 12 weeks and progression-free survival (PFS) after random assignment.ResultsOne hundred seventy-one men with CRPC were enrolled. Random assignment was halted early based on the observed activity of cabozantinib. Seventy-two percent of patients had regression in soft tissue lesions, whereas 68% of evaluable patients had improvement on bone scan, including complete resolution in 12%. The objective response rate at 12 weeks was 5%, with stable disease in 75% of patients. Thirty-one patients with stable disease at week 12 were randomly assigned. Median PFS was 23.9 weeks (95% CI, 10.7 to 62.4 weeks) with cabozantinib and 5.9 weeks (95% CI, 5.4 to 6.6 weeks) with placebo (hazard ratio, 0.12; P < .001). Serum total alkaline phosphatase and plasma cross-linked C-terminal telopeptide of type I collagen were reduced by ≥ 50% in 57% of evaluable patients. On retrospective review, bone pain improved in 67% of evaluable patients, with a decrease in narcotic use in 56%. The most common grade 3 adverse events were fatigue (16%), hypertension (12%), and hand-foot syndrome (8%).ConclusionCabozantinib has clinical activity in men with CRPC, including reduction of soft tissue lesions, improvement in PFS, resolution of bone scans, and reductions in bone turnover markers, pain, and narcotic use.

Published
2013

9. Supplementary Figure 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Table 4 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 3 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure Legends from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Methods from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 3 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Author

Shapiro, Geoffrey I., primary, Rodon, Jordi, primary, Bedell, Cynthia, primary, Kwak, Eunice L., primary, Baselga, Jose, primary, Braña, Irene, primary, Pandya, Shuchi S., primary, Scheffold, Christian, primary, Laird, A. Douglas, primary, Nguyen, Linh T., primary, Xu, Yi, primary, Egile, Coumaran, primary, and Edelman, Gerald, primary

Published
2023
Full Text
View/download PDF

18. Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.

Author

Burotto, Mauricio, primary, Powles, Thomas, additional, Escudier, Bernard, additional, Apolo, Andrea B., additional, Bourlon, Maria Teresa, additional, Shah, Amishi Yogesh, additional, Suárez, Cristina, additional, Porta, Camillo, additional, Barrios, Carlos H., additional, Richardet, Martin, additional, Gurney, Howard, additional, Kessler, Elizabeth R, additional, Tomita, Yoshihiko, additional, Bedke, Jens, additional, George, Saby, additional, Scheffold, Christian, additional, Wang, Peter, additional, Fedorov, Viktor, additional, Motzer, Robert J., additional, and Choueiri, Toni K., additional

Published
2023
Full Text
View/download PDF

19. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Author

Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Tannir, Nizar M, Mainwaring, Paul N, Rini, Brian I, Hammers, Hans J, Donskov, Frede, Roth, Bruce J, Peltola, Katriina, Lee, Jae Lyun, Heng, Daniel Y C, Schmidinger, Manuela, Agarwal, Neeraj, Sternberg, Cora N, McDermott, David F, Aftab, Dana T, Hessel, Colin, Scheffold, Christian, Schwab, Gisela, Hutson, Thomas E, Pal, Sumanta, and Motzer, Robert J

Published
2016
Full Text
View/download PDF

20. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial

Author

Yau, Thomas, primary, Zagonel, Vittorina, additional, Santoro, Armando, additional, Acosta-Rivera, Mirelis, additional, Choo, Su Pin, additional, Matilla, Ana, additional, He, Aiwu Ruth, additional, Cubillo Gracian, Antonio, additional, El-Khoueiry, Anthony B., additional, Sangro, Bruno, additional, Eldawy, Tarek E., additional, Bruix, Jordi, additional, Frassineti, Giovanni Luca, additional, Vaccaro, Gina M., additional, Tschaika, Marina, additional, Scheffold, Christian, additional, Koopmans, Petra, additional, Neely, Jaclyn, additional, and Piscaglia, Fabio, additional

Published
2022
Full Text
View/download PDF

22. A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 in subjects with inoperable locally advanced or metastatic solid tumors (301)

Author

Tolcher, Anthony, primary, Vandross, Andrae, additional, Johnson, Melissa, additional, Park, Haeseong, additional, Scheffold, Christian, additional, Li, Jing, additional, Bekele, Neby, additional, Uttamsingh, Shailaja, additional, Faggioni, Raffaella, additional, and Ulahannan, Susanna, additional

Published
2022
Full Text
View/download PDF

24. Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER.

Author

Suárez, Cristina, primary, Choueiri, Toni K., additional, Burotto, Mauricio, additional, Powles, Thomas, additional, Bourlon, Maria Teresa, additional, Shah, Amishi Yogesh, additional, Tomita, Yoshihiko, additional, Bedke, Jens, additional, Zhang, Joshua, additional, Simsek, Burcin, additional, Scheffold, Christian, additional, Escudier, Bernard, additional, Motzer, Robert J., additional, and Apolo, Andrea B., additional

Published
2022
Full Text
View/download PDF

25. Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.

Author

Neal, Joel W., primary, Santoro, Armando, additional, Viteri, Santiago, additional, Ponce Aix, Santiago, additional, Fang, Bruno, additional, Lim, Farah Louise, additional, Gentzler, Ryan D., additional, Goldschmidt, Jerome H., additional, Khrizman, Polina, additional, Massarelli, Erminia, additional, Patel, Shiven B., additional, Puri, Sonam, additional, Sudhagoni, Ramu, additional, Scheffold, Christian, additional, Curran, Dominic, additional, and Felip, Enriqueta, additional

Published
2022
Full Text
View/download PDF

26. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.

Author

Yau, Thomas, Zagonel, Vittorina, Santoro, Armando, Acosta-Rivera, Mirelis, Choo, Su Pin, Matilla, Ana, He, Aiwu Ruth, Cubillo Gracian, Antonio, El-Khoueiry, Anthony B., Sangro, Bruno, Eldawy, Tarek E., Bruix, Jordi, Frassineti, Giovanni Luca, Vaccaro, Gina M., Tschaika, Marina, Scheffold, Christian, Koopmans, Petra, Neely, Jaclyn, and Piscaglia, Fabio

Published
2023
Full Text
View/download PDF

27. Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.

Author

Powles, Thomas, primary, Choueiri, Toni K., additional, Burotto, Mauricio, additional, Escudier, Bernard, additional, Bourlon, Maria Teresa, additional, Shah, Amishi Yogesh, additional, Suárez, Cristina, additional, Hamzaj, Alketa, additional, Porta, Camillo, additional, Hocking, Christopher, additional, Kessler, Elizabeth R, additional, Gurney, Howard, additional, Tomita, Yoshihiko, additional, Bedke, Jens, additional, Zhang, Joshua, additional, Simsek, Burcin, additional, Scheffold, Christian, additional, Apolo, Andrea B., additional, and Motzer, Robert J., additional

Published
2022
Full Text
View/download PDF

28. Abstract OT2-01-02: First in human phase 1 dose escalation and expansion study of the safety and pharmacokinetics of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients with inoperable locally advanced or metastatic solid tumors, including breast cancer

Author

Patnaik, Amita, primary, Barve, Minal, additional, Bhave, Manali, additional, Subbiah, Vivek, additional, Atwal, Sumandeep, additional, Sharma, Keerti, additional, Scheffold, Christian, additional, Wetmore, Cynthia, additional, and Shapiro, Geoffrey, additional

Published
2022
Full Text
View/download PDF

29. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

Author

Pal, Sumanta K., primary, McGregor, Bradley, additional, Suárez, Cristina, additional, Tsao, Che-Kai, additional, Kelly, William, additional, Vaishampayan, Ulka, additional, Pagliaro, Lance, additional, Maughan, Benjamin L., additional, Loriot, Yohann, additional, Castellano, Daniel, additional, Srinivas, Sandy, additional, McKay, Rana R., additional, Dreicer, Robert, additional, Hutson, Thomas, additional, Dubey, Sarita, additional, Werneke, Scott, additional, Panneerselvam, Ashok, additional, Curran, Dominic, additional, Scheffold, Christian, additional, Choueiri, Toni K., additional, and Agarwal, Neeraj, additional

Published
2021
Full Text
View/download PDF

30. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Author

Choueiri, Toni K., Escudier, Bernard, Powles, Thomas, Mainwaring, Paul N., Rini, Brian I., Donskov, Frede, Hammers, Hans, Hutson, Thomas E., Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J., Bjarnason, Georg A., Géczi, Lajos, Keam, Bhumsuk, Maroto, Pablo, Heng, Daniel Y.C., Schmidinger, Manuela, Kantoff, Philip W., Borgman-Hagey, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M., Tannir, Nizar M., and Motzer, Robert J.

Published
2015
Full Text
View/download PDF

32. Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.

Author

Apolo, Andrea B., primary, Powles, Thomas, additional, Burotto, Mauricio, additional, Bourlon, Maria Teresa, additional, Hsieh, James J, additional, Basso, Umberto, additional, Shah, Amishi Yogesh, additional, Suarez, Cristina, additional, Porta, Camillo, additional, Barrios, Carlos H., additional, Gurney, Howard, additional, Kessler, Elizabeth R, additional, Retz, Margitta, additional, George, Saby, additional, Escudier, Bernard, additional, Zhang, Joshua, additional, Simsek, Burcin, additional, Scheffold, Christian, additional, Motzer, Robert J., additional, and Choueiri, Toni K., additional

Published
2021
Full Text
View/download PDF

33. Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).

Author

Shah, Amishi Yogesh, primary, Motzer, Robert J., additional, Apolo, Andrea B., additional, Powles, Thomas, additional, Escudier, Bernard, additional, Zhang, Joshua, additional, Scheffold, Christian, additional, Karumanchi, Sravan, additional, Nguyen, Linh Thuy, additional, and Choueiri, Toni K., additional

Published
2021
Full Text
View/download PDF

34. Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.

Author

Motzer, Robert J., primary, Choueiri, Toni K., additional, Powles, Thomas, additional, Burotto, Mauricio, additional, Bourlon, Maria Teresa, additional, Hsieh, James J, additional, Maruzzo, Marco, additional, Shah, Amishi Yogesh, additional, Suarez, Cristina, additional, Barrios, Carlos H., additional, Richardet, Martin Eduardo, additional, Porta, Camillo, additional, Goh, Jeffrey C., additional, Tomita, Yoshihiko, additional, Bedke, Jens, additional, Zhang, Joshua, additional, Simsek, Burcin, additional, Scheffold, Christian, additional, Gupta, Saurabh, additional, and Apolo, Andrea B., additional

Published
2021
Full Text
View/download PDF

35. CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.

Author

Pal, Sumanta K., primary, Albiges, Laurence, additional, Suarez Rodriguez, Cristina, additional, Liu, Bo, additional, Doss, Jennifer, additional, Khurana, Sudha, additional, Scheffold, Christian, additional, Voss, Martin H, additional, and Choueiri, Toni K., additional

Published
2021
Full Text
View/download PDF

39. Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma

Author

Tannir, Nizar M., primary, Powles, Thomas, additional, Escudier, Bernard, additional, Donskov, Frede, additional, Grünwald, Viktor, additional, Sternberg, Cora N., additional, Schmidinger, Manuela, additional, Schöffski, Patrick, additional, Szczylik, Cezary, additional, Peltolta, Katriina, additional, Nosov, Dmitry, additional, Melichar, Bohuslav, additional, Clary, Douglas, additional, Scheffold, Christian, additional, Motzer, Robert J., additional, and Choueiri, Toni K., additional

Published
2020
Full Text
View/download PDF

41. Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

Author

Yau, Thomas, primary, Zagonel, Vittorina, additional, Santoro, Armando, additional, Acosta-Rivera, Mirelis, additional, Choo, Su Pin, additional, Matilla, Ana, additional, He, Aiwu Ruth, additional, Cubillo Gracián, Antonio, additional, El-Khoueiry, Anthony B., additional, Sangro, Bruno, additional, Eldawy, Tarek, additional, Bruix, Jordi, additional, Frassineti, Giovanni, additional, Vaccaro, Gina M., additional, Tschaika, Marina, additional, Scheffold, Christian, additional, Shen, Yun, additional, Neely, Jaclyn, additional, and Piscaglia, Fabio, additional

Published
2020
Full Text
View/download PDF

45. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets

Author

Stelljes, Matthias, Strothotte, Robert, Pauels, Hans-Gerd, Poremba, Christopher, Milse, Michaela, Specht, Christiane, Albring, Jörn, Bisping, Guido, Scheffold, Christian, Kammertoens, Thomas, Oelmann, Elisabeth, Silling, Gerda, Berdel, Wolfgang E., and Kienast, Joachim

Published
2004
Full Text
View/download PDF

49. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

Author

George, Daniel J., primary, Hessel, Colin, additional, Halabi, Susan, additional, Michaelson, M. Dror, additional, Hahn, Olwen, additional, Walsh, Meghara, additional, Picus, Joel, additional, Small, Eric J., additional, Dakhil, Shaker, additional, Feldman, Darren R., additional, Mangeshkar, Milan, additional, Scheffold, Christian, additional, Morris, Michael J., additional, and Choueiri, Toni K., additional

Published
2019
Full Text
View/download PDF

50. Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]

Author

Choueiri, Toni K., primary, Hessel, Colin, additional, Halabi, Susan, additional, Sanford, Ben, additional, Michaelson, M. Dror, additional, Hahn, Olwen, additional, Walsh, Meghara, additional, Olencki, Thomas, additional, Picus, Joel, additional, Small, Eric J., additional, Dakhil, Shaker, additional, Feldman, Darren R., additional, Mangeshkar, Milan, additional, Scheffold, Christian, additional, George, Daniel, additional, and Morris, Michael J., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results